Advancedadvanced biology
Cell Cycle Checkpoints: Guarding the Genome
Learning objectives
- Explain the G1/S restriction point and the Rb-E2F bistable switch.
- Describe G2/M control through Wee1, Cdc25, and CDK1-cyclin B.
- Trace spindle assembly checkpoint signaling from unattached kinetochores to APC/C inhibition.
- Evaluate how DNA-damage checkpoints (ATM/ATR-Chk1/Chk2-p53) arrest the cycle.
- Relate checkpoint loss to genomic instability and cancer therapy.
The G1/S restriction point: the commitment decision
In G1, the cell decides whether to divide at all. Mitogens drive expression of D-type cyclins, which activate CDK4 and CDK6; these kinases begin phosphorylating the retinoblastoma protein Rb, the gatekeeper of the G1/S transition. Hypophosphorylated Rb binds and inhibits E2F transcription factors; as CDK4/6 (and then CDK2-cyclin E) phosphorylate Rb progressively, E2F is released and drives transcription of S-phase genes -- including cyclin E itself, creating a positive feedback loop that makes the transition switch-like and irreversible. Past this restriction point, the cell is committed: withdrawing mitogens no longer stops S-phase entry. The INK4 family (p16) inhibits CDK4/6, and p21/p27 inhibit CDK2, providing brakes that DNA damage (via p53-induced p21) or anti-growth signals can engage. Loss of Rb -- the founding tumor suppressor, discovered in retinoblastoma -- removes the gate entirely, which is why the Rb pathway is disrupted in the great majority of human cancers.
G2/M: the mitotic entry switch
Entry into mitosis is governed by CDK1 bound to cyclin B -- the original M-phase promoting factor. Through G2, CDK1-cyclin B accumulates but is held inactive by Wee1-mediated inhibitory phosphorylation; activation requires the Cdc25 phosphatase to remove those phosphates. The switch is sharpened by feedback: active CDK1 further activates Cdc25 and inhibits Wee1, creating a bistable, all-or-none transition into mitosis -- the cell does not half-enter M phase. DNA damage in G2 engages the checkpoint kinases Chk1/Chk2, which inhibit Cdc25 (via sequestration and degradation), holding CDK1 off and arresting the cell in G2 until repair completes. The G2/M checkpoint also monitors completion of DNA replication: unfinished replication generates single-stranded DNA that activates ATR, enforcing the arrest. Premature mitotic entry with damaged or under-replicated DNA causes mitotic catastrophe -- chromosomes shattering as the spindle pulls on broken templates -- which is why this checkpoint is a major determinant of radiation and chemotherapy response.
The spindle assembly checkpoint: waiting for attachment
The spindle assembly checkpoint (SAC) is the most mechanically beautiful checkpoint: it monitors whether every kinetochore is attached to spindle microtubules and under tension, and delays anaphase until all are. Unattached kinetochores serve as catalytic platforms where Mad1/Mad2 convert open Mad2 into closed Mad2, which with BubR1 and Bub3 forms the mitotic checkpoint complex (MCC) -- a diffusible inhibitor of the anaphase-promoting complex/cyclosome (APC/C). The APC/C is the ubiquitin ligase that would otherwise destroy securin (releasing separase to cleave cohesin) and cyclin B (exiting mitosis); by inhibiting it, even a single unattached kinetochore holds the entire cell in metaphase. Once the last kinetochore attaches and comes under tension, MCC production stops, existing MCC is disassembled, APC/C activates, and anaphase begins -- synchronously, irreversibly. The SAC is why spindle poisons like taxol and vinca alkaloids arrest cells in mitosis: by disrupting microtubule dynamics they keep kinetochores signaling, and prolonged arrest drives apoptosis -- the basis of their anticancer activity.
DNA-damage checkpoints: ATM, ATR, and p53
DNA damage checkpoints operate at G1/S, intra-S, and G2/M through two apical kinases: ATM, activated by double-strand breaks (sensed by the MRN complex), and ATR, activated by single-stranded DNA coated with RPA (arising at stalled replication forks or resected breaks). ATM and ATR phosphorylate the effector kinases Chk2 and Chk1 respectively, which inactivate Cdc25 phosphatases -- immediately halting cycle progression -- and stabilize p53 by phosphorylating it and its negative regulator MDM2. p53 then transcribes p21 (arresting CDK2), GADD45, 14-3-3sigma, and pro-apoptotic genes, converting a transient kinase signal into a sustained transcriptional program: arrest and repair, or senescence, or apoptosis if damage is irreparable. The choice between arrest and death depends on damage level, cell type, and p53's post-translational modifications -- a single transcription factor integrating severity into fate. Inherited defects (ATM in ataxia-telangiectasia, BRCA1/2 in homologous recombination) reveal each component's non-redundant role.
Checkpoints lost: instability and therapeutic opportunity
Cancer is, in one view, a disease of broken checkpoints: p53 mutated in half of tumors, Rb pathway disrupted in most of the rest, SAC weakened in chromosomally unstable cancers. Checkpoint loss does not merely accelerate division -- it permits the propagation of damaged genomes, generating the heterogeneity and aneuploidy that fuel tumor evolution and drug resistance. Paradoxically, this creates therapeutic leverage: checkpoint-defective cancer cells depend hyper-actively on their remaining checkpoints, a synthetic-lethal logic. PARP inhibitors kill BRCA-deficient tumors by blocking backup repair; WEE1 inhibitors force checkpoint-compromised cells into premature mitosis; CDK4/6 inhibitors (palbociclib and successors) restore the G1/S gate pharmacologically in Rb-proficient breast cancers. The emerging principle is checkpoint therapy: rather than poisoning division generally, exploit the specific surveillance the tumor has lost -- turning the cancer's own genomic carelessness into its vulnerability.
The spindle assembly checkpoint is exquisitely sensitive: a single unattached kinetochore generates enough mitotic checkpoint complex to inhibit all APC/C in the cell. Anaphase waits for the last chromosome.
Key points
- The G1/S restriction point is a bistable Rb-E2F switch driven by CDK4/6 and CDK2; past it, mitogen withdrawal cannot stop S-phase entry.
- G2/M entry is an all-or-none CDK1-cyclin B switch sharpened by Wee1/Cdc25 feedback; DNA damage holds it off via Chk1/Chk2.
- The spindle assembly checkpoint uses unattached kinetochores to generate MCC, inhibiting APC/C until every chromosome is bioriented.
- ATM (double-strand breaks) and ATR (single-stranded DNA) signal through Chk2/Chk1 and p53 to arrest, repair, senesce, or apoptose.
- Checkpoint loss drives genomic instability in cancer but creates synthetic-lethal vulnerabilities exploited by PARP, WEE1, and CDK4/6 inhibitors.
Common misconceptions
✓ Truth: They are signal-transduction cascades that actively inhibit the cycle machinery (Cdc25, APC/C) and launch transcriptional programs -- pausing is the least of what they do.
✓ Truth: p53 is a transcription factor; it induces p21 and other effectors that inhibit CDKs. The arrest is executed by its target genes, not by p53 binding the machinery.
✓ Truth: It monitors attachment and tension at kinetochores, not number -- a single unattached kinetochore, regardless of ploidy, generates the wait signal.
Frequently asked questions
What is the restriction point?
The G1 commitment decision: once CDK4/6 and CDK2 have phosphorylated Rb and released E2F, positive feedback makes S-phase entry irreversible even if mitogens are withdrawn.
How does the spindle assembly checkpoint work?
Unattached kinetochores catalyze formation of the mitotic checkpoint complex (Mad2-BubR1-Bub3), which inhibits the APC/C ubiquitin ligase, blocking securin and cyclin B destruction until all kinetochores attach.
What is the difference between ATM and ATR?
ATM responds to double-strand breaks via the MRN sensor; ATR responds to RPA-coated single-stranded DNA at stalled forks or resected breaks. They signal through Chk2 and Chk1 respectively.
Why do spindle poisons kill cancer cells?
Taxol and vinca alkaloids disrupt microtubule dynamics, keeping kinetochores unattached; the SAC arrests cells in mitosis prolonged enough to trigger apoptosis.
What is synthetic lethality in checkpoint therapy?
Killing cells by blocking the backup pathway they depend on after losing the primary one -- e.g., PARP inhibitors in BRCA-deficient tumors, WEE1 inhibitors in checkpoint-compromised cells.